Winner of the Best Clinical Trial Site Network: Clinical Research Advantage @ViE Awards

best clinical trial network CRA world vaccine congress

This Award recognizes those domestic and international trial sites, who are demonstrating unsurpassed service levels to CROs and its sponsors.
The criteria used to judge this category will be as follows:

•    Range and reach of the networks' independently-owned, geographically diverse research sites specializing in active multi-therapeutic vaccine trials
•    Provision to clinical Sponsors / CROs the ability to engage multiple network members in multi-sized studies requiring diverse multiple sites/populations
•    Services that maximize sponsor/CRO economies of scale, consistency and self-assessment that ensure oversight and study/trial efficiencies
•    Mentoring capabilities to support timely goal attainment, study completion and related efficiencies, cost containment measures, consistent and accurate data collection, validation and enrolment / retention processes
•    Forging of on-going partnerships with Sponsors / CRO’s necessary for future trial participation opportunities

Winner: Clinical Research Advantage

clinical research advantagex200


Judges specific comments on the winner included:

1. In 2011 this Site Network added 6 additional sites and 2 additional geographic markets, bringing the total to 33 sites across 17 diverse geographic markets nationwide, enrolling 2,754 vaccine subjects (133% of sponsor goal) in  the last 12 months
2. This site network conducted 44 multi-therapeutic vaccine trials in 2011 for Tetanus, HSV, H5N1, Influenza, Shingles, HPV, Hepatitis, Pneumonia, Meningitis and C-difficile vaccine candidates, including a large-scale influenza vaccine study engaged by 8 of their network sites.

Well done Clinical Research Advantage


Highly Regarded' recommendation: VaxNet for their pioneering of a ‘performance report card' that has increased their site QA/QC and efficiency.

Leave a Reply

Your email address will not be published. Required fields are marked *